AUPH vs. IRON, NRIX, ALXO, SVRA, PRAX, PRTC, PHAR, ELVN, TYRA, and YMAB
Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include Disc Medicine (IRON), Nurix Therapeutics (NRIX), ALX Oncology (ALXO), Savara (SVRA), Praxis Precision Medicines (PRAX), PureTech Health (PRTC), Pharming Group (PHAR), Enliven Therapeutics (ELVN), Tyra Biosciences (TYRA), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.
Aurinia Pharmaceuticals (NASDAQ:AUPH) and Disc Medicine (NASDAQ:IRON) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.
Aurinia Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 103.67%. Disc Medicine has a consensus target price of $57.29, suggesting a potential upside of 107.93%. Given Disc Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Disc Medicine is more favorable than Aurinia Pharmaceuticals.
In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 2 articles in the media. Disc Medicine's average media sentiment score of 0.53 beat Aurinia Pharmaceuticals' score of 0.15 indicating that Disc Medicine is being referred to more favorably in the news media.
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 4.7% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Aurinia Pharmaceuticals received 543 more outperform votes than Disc Medicine when rated by MarketBeat users. Likewise, 73.03% of users gave Aurinia Pharmaceuticals an outperform vote while only 71.88% of users gave Disc Medicine an outperform vote.
Disc Medicine has lower revenue, but higher earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.
Aurinia Pharmaceuticals has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500.
Disc Medicine has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -44.45%. Aurinia Pharmaceuticals' return on equity of -20.10% beat Disc Medicine's return on equity.
Summary
Disc Medicine beats Aurinia Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Aurinia Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurinia Pharmaceuticals Competitors List
Related Companies and Tools
